Web of Science: 36 cites, Scopus: 43 cites, Google Scholar: cites,
The International Rare Diseases Research Consortium : Policies and Guidelines to maximize impact
Lochmüller, Hanns (Newcastle Upon Tyne, UK)
Torrent i Farnell, Josep (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Le Cam, Yann (Paris, France)
Jonker, Anneliene H (IRDiRC Scientific Secretariat, Inserm US-14, Paris, France)
Lau, Lilian PL (IRDiRC Scientific Secretariat, Inserm US-14, Paris, France)
Baynam, Gareth (Western Australian Register of Developmental Anomalies, WA Perth, Australia)
Kaufmann, Petra (Bethesda, MD USA)
Dawkins, Hugh JS (Perth, WA Australia)
Lasko, Paul (Montréal, QC Canada)
Austin, Christopher P (Bethesda, MD USA)
Boycott, Kym M (Ottawa, ON Canada)

Data: 2017
Resum: The International Rare Diseases Research Consortium (IRDiRC) has agreed on IRDiRC Policies and Guidelines, following extensive deliberations and discussions in 2012 and 2013, as a first step towards improving coordination of research efforts worldwide. The 25 funding members and 3 patient umbrella organizations (as of early 2013) of IRDiRC, a consortium of research funders that focuses on improving diagnosis and therapy for rare disease patients, agreed in Dublin, Ireland in April 2013 on the Policies and Guidelines that emphasize collaboration in rare disease research, the involvement of patients and their representatives in all relevant aspects of research, as well as the sharing of data and resources. The Policies and Guidelines provide guidance on ontologies, diagnostics, biomarkers, patient registries, biobanks, natural history, therapeutics, models, publication, intellectual property, and communication. Most IRDiRC members-currently nearly 50 strong-have since incorporated its policies in their funding calls and some have chosen to exceed the requirements laid out, for instance in relation to data sharing. The IRDiRC Policies and Guidelines are the first, detailed agreement of major public and private funding organizations worldwide to govern rare disease research, and may serve as a template for other areas of international research collaboration. While it is too early to assess their full impact on research productivity and patient benefit, the IRDiRC Policies and Guidelines have already contributed significantly to improving transparency and collaboration in rare disease research.
Nota: Altres ajuts: This work and the IRDiRC Scientific Secretariat are supported by the European FP7 contract, "SUPPORT-IRDiRC" (No 305207). H.L. receives funding from the European Commission under FP7 through NeurOmics (No 305121) and RD-Connect (No 305444). C.P.A. contributed to this work in his capacity as Chair of the IRDiRC Consortium Assembly, not as Director of the NCATS. The remaining authors declare that they have no competing interests.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Publicat a: European Journal of Human Genetics, Vol. 25 (november 2017) , p. 1293-1302, ISSN 1476-5438

DOI: 10.1038/s41431-017-0008-z
PMID: 29158551


10 p, 1.0 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-06-18, darrera modificació el 2022-02-06



   Favorit i Compartir